key: cord-0949940-ziejplfr authors: Beressa, T. B.; Sahilu, T.; Deyno, S. title: Effect of Renin-Angiotensin-Aldosterone System inhibitors on outcomes of COVID-19 patients with hypertension: Systematic review and Meta-analysis date: 2020-09-04 journal: nan DOI: 10.1101/2020.09.03.20187393 sha: 79150907e5f6b2faaa8e76559eb0f207340cab6c doc_id: 949940 cord_uid: ziejplfr Objective: This research aimed to systematically review and summarize the influence of Renin-Angiotensin-Aldosterone System (RAAS) inhibitors on the outcome of COVID_19 patients with hypertension. Methods: Electronic databases; PubMed/Medline, CINAHL, the Cochrane Central Register of Controlled Trials, clinical trial.gov, and Google Scholar were searched from 2019 to June 1, 2020. Additionally, the references of identified articles were also searched. Results: A total of 9 articles comprising 3,823 patients were incorporated; 1416 patients on RAAS inhibitors and 3469 on non-RAAS inhibitors. The study demonstrated that the taking of RAAS inhibitors in COVID_19 patients with hypertension significantly reduced mortality where patients on RAAS inhibitors had a 27% decrease of mortality (RR= 0.73 [95% CI: 0.63- 0.85, p<0.0001, I2=0%, random-effects model]) compared to those not taking ACEI/ARB. No significant association were observed in disease severity (RR= 0.92 (95% CI: 0.74- 1.14) and hospitalization (WMD= -2.33[95% CI: -5.60, 0.75]), random-effects model. Conclusion: This study supports RAAS inhibitors safe use among COVID_19 patients with hypertension. Keywords: COVID_19, ACEI, ARB, Hypertension, Coronavirus Corona viral diseases 2019 (COVID_19) is a pandemic disease originated from Wuhan city of, China from December 2019 1 . The pandemic has continued to debilitate global health and the economy. As of June 7, 2020; 7,005,822 cases of COVID_19 were reported, including 402,678 deaths worldwide 2 . Severe COVID_19 illnesses have consistently been observed in patients with Comorbid illnesses such as cardiovascular and diabetes mellitus 3 . According to the report of the Chinese CDC as of February 11, 2020, 10 .5% of deaths occurred in COVID_19 patients with cardiovascular diseases and, 6% of them were patients with hypertension 3 . Most patients with cardiovascular disease use RAAS inhibitors; commonly angiotensinconverting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) 4 . They are a drug of choice for heart failure, hypertension, chronic kidney disease and, myocardial infraction 5, 6 . Besides inhibition of the formation of angiotensin II; RAAS inhibitors increase the expression of angiotensin-converting enzyme 2 (ACE2); a membrane-bound aminopeptidase that is expressed abundantly in the lungs and the heart 7 . ACE2 plays an important role in the breakdown of angiotensin II (a potent vasoconstrictor) to angiotensin (1-7) (a vasodilator) 8 which helpful in cardiovascular patients. Researches reported that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) attacks the humans cells through ACE2 9, 10 , and reduces ACE2 expression, resulting imbalance of ACE/Ang II/AT1R axis and ACE2/Ang (1-7)/Mas receptor 11, 12 . Therefore; there are concerns about the use of RAAS inhibitors as a result of an increase in expression of ACE2; a target molecule for SARS CoV-2 [13] [14] [15] . This led to the hypothesis that the use of RAAS inhibitors might be harmful in patient with COVID_19 especially in patients with comorbidity like . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 4, 2020. . https://doi.org/10.1101/2020.09.03.20187393 doi: medRxiv preprint hypertension. There are retrospective studies conducted to test this hypothesis and one metaanalysis (preprint)summarized the studies in all patients taking RAAS inhibitors 16 . The metaanalysis included 1842 COVID_19 patients and exhibited a significant 43 % decrease in mortality on the side of patients taking ACEI/ARB 16 . After the meta-analysis several studies were conducted which requires updating the evidence and also there is a need for evidence on hypertensive patients. This study aimed to systematically synthesis the evidence on the effect of RAAS inhibitors on the outcome of COVID_19 patients with hypertension. This is a systematic review and meta-analysis conducted using electronic database searches. The review conducted according to the preferred reporting items for Systematic Review and Meta-Analysis Protocol (PRISMA) 17 . The protocol was registered in the (Prospero) International Prospective Register of a systematic review with registration number CDR42020186477. The databases such as PubMed, the Cochrane Central Register of controlled trials, clinical trial.gov, CINAHIL, and Google scholar were searched from 2019 to June 1, 2020. Additionally, the references of identified articles were also searched. No language limitation was employed. Flow diagram was used to summarize the number of studies identified, screened, excluded, and finally included in the study. Search terms for PubMed were attached under the supplementary document (Appendix 1). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 4, 2020. . https://doi.org/10.1101/2020.09.03.20187393 doi: medRxiv preprint Two reviewers (TB and TS) independently carried out searching for literature and identified relevant studies and sequentially screened their titles and abstracts for eligibility. The full texts of eligible studies were retrieved. Differences in the inclusion of articles were fixed on discussion with the third author (SD). A screening guide was used to ensure that all review authors applied the selection criteria. Randomized controlled trials (RCTs) including cluster RCTs, observational studies, and prospective, retrospective comparative cohort studies and case-control studies were considered to be included in the systematic review and meta-analysis. The review considered all patients who were taking ACEI or ARBs alone or in combination for hypertension with COVID-19 patients. In vitro studies, studies not related to ARB or ACEI for COVID-19 patients with hypertension, studies without extractable data, outcome (death), or severity or hospitalization not clearly reported were excluded from the review. Selected papers were evaluated by two reviewers (TB & TS) for methodological validity before inclusion in the review with the Newcastle-Ottawa quality assessment score (NOS) method. Any differences that arose from the reviewers were fixed through discussion, with a third reviewer (SD). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 4, 2020. . https://doi.org/10.1101/2020.09.03.20187393 doi: medRxiv preprint Two reviewers (TB and TS) extracted data from the studies using a pre-designed format. Data extracted include first author, the region of study, included population, study design, number of study participants, comparator group, patient status, severity, age (mean, median), gender, interventions, and patients outcomes (number of cases). Data analysis was performed by RevMan 5.4 (Copenhagen: the Cochrane Collaboration, 2020) and Stata version 13 (StataCorp, 2013). Risk ratios were used for comparison and reported as 95% confidence interval. P-value ≤ 0.05 was considered statistically significant. The Q-statistic test was used to assess the heterogeneity of the included study and I 2 statistic was used to indicate the percentage of variation in the studies as a result of heterogeneity instead of chance. A total of 608 articles were identified through searching of electronic databases, out of this 554 remained after removing duplications. After screening in title and abstract 112 articles remained; of which 105 articles (review articles and letters to editors) were excluded. Finally, 9 articles were included for meta-analysis [18] [19] [20] [21] [22] [23] [24] [25] [26] (Fig 1) . A total number of 3,823 patients were included; 1416 patients on RAAS inhibitors and 3469 on non-RAAS inhibitors (Fig 2) . Newcastle-Ottawa Scale methodological quality assessment gave the quality of the included studies in good arrangement (Appendix 2). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 4, 2020. . https://doi.org/10.1101/2020.09.03.20187393 doi: medRxiv preprint Full-text articles excluded with reasons (n =105 ) Studies included in metaanalysis (n = 9) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 4, 2020. . https://doi.org/10.1101/2020.09.03.20187393 doi: medRxiv preprint February 2020 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 4, 2020. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 4, 2020. . https://doi.org/10.1101/2020.09.03.20187393 doi: medRxiv preprint Seven studies reported the mortality data of the hypertensive COVID_19 patients. No heterogeneity was observed among the 7 studies (I 2 = 0%, P=0.59). The pooled mortality was RR= 0.73 (95% CI: 0.63-0.85), fixed effect model Fig. 3 . The funnel plot was used to assess the publication bias. Funnel plot indicates the existence of small study effects. We performed the regression-based on Egger's test. The funnel plot was symmetrical in shape for severity and mortality (Fig 5 and 6) , indicating no publication bias. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 4, 2020. . https://doi.org/10.1101/2020.09.03.20187393 doi: medRxiv preprint Regression-based Egger's test indicates that there were no small-study effects on mortality (P=0.122) and severe events (p = 0.686). This study, however, was in contrast to the original hypothesis demonstrating the safe usage of RAAS inhibitors in hypertensive COVID_19 patients; in this, it was associated with a significant reduction in mortality. The hypertensive patients with COVID_19 who were on ACE/ARB had a 27% reduction in risk of mortality compared to that not on ACEI/ARB. This finding is helpful and should be considered in clinical decision making. Two large sample size studies, 18 and 21 , reported a reduction in mortality with patients on ARBs/ACEIs compared to those on non-ARBs/ACEIs medications. A study compared the use of other antihypertensive drugs with ACEI/ARB revealed that ACEI/ARB significantly reduced mortality in COVID_19 patients with hypertension 23 . RAAS inhibitors thought to up-regulate the level of ACE2 which may protect against organ damage by inhibiting the production of angiotensin II 32 . Moreover, the study showed that patients with COVID_19 appeared to exhibit RAAS activation, increased viral load levels, and lung injury 33 . However, all five small sample studies did not show any association with mortality [20] [21] [22] [23] [24] . Emerging data suggested that patients with hypertension and diagnosed with . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 4, 2020. . https://doi.org/10.1101/2020.09.03.20187393 doi: medRxiv preprint COVID_19 are at an increased risk of death 34 . These patients have often prescribed RAAS inhibitors, including ACE inhibitors 35 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 4, 2020. A novel coronavirus from patients with pneumonia in China COVID-19): situation report-139. 2020. 3. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use Pharmacologic modulation of ACE2 expression Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 Physiology of local renin-angiotensin systems Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1-7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus A pneumonia outbreak associated with a new coronavirus of probable bat origin A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2 Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19 The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis. medRxiv The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. medRxiv Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension. medRxiv Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. medRxiv Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19 Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust. medRxiv Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv ACE inhibitors, ARBs and other anti-hypertensive drugs and novel COVID-19: An association study from the COVID Symptom tracker app in 2,215,386 individuals Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19 Association of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19-Related Outcome. Available at SSRN 3569837 Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19 Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury COVID-19 and the cardiovascular system The role of experience in problem solving and innovative tool use in crows Renin-angiotensin-aldosterone system inhibitors and COVID-19 The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade OR valsartan OR atacand OR candesartan OR cozaar OR losartan OR micardis OR avapro OR edarbi OR irbesartan OR "azilsartan medoxomil" OR prexxartan OR valsartan) AND ("sarscoronavirus" OR "sars-cov-2" OR "severe acute respiratory syndrome" OR coronavir* OR coronovirus* OR "corona virus" OR "corono virus" OR "corono virus" OR Not applicable Gao 2020 * * * * ** * * * Good